Temporomandibular Joint Arthrocentesis With Infiltration of PRP + Ropivacaine Versus PRP
Status:
Enrolling by invitation
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The infiltration of Platelet Rich Plasma (PRP) at the end of Temporomandibular Joint (TMJ)
arthrocentesis is already an established procedure in the treatment of Temporomandibular
Disorders (TMD). Arthrocentesis is a minimally invasive surgical procedure, which aims to
eliminate the inflammatory mediators from the inside of the TMJ. PRP is an autologous
concentrate of platelets and growth factors, derived from centrifugated blood. Several
studies have described the benefits of PRP: it enhances wound healing because of the presence
of cytokines and growth factors, and is also stimulates chondrocytes to biosynthesis of
collagen. Ropivacaine is a local anesthetic that has been synthesized for use in infiltration
anesthesia and to produce both peripheral and central block. Unlike one of its analogues,
Bupivacaine, Ropivacaine anesthetize the sensory fibers without affecting the motor ones. The
main goal of this investigation is to test the benefits of adding Ropivacaine to the
infiltration of PRP in patients submitted to TMJ arthrocentesis.